Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in Breast cancer
NCT05959889Completed
- Sponsor
- Damanhour University
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of montelukast in Cardiotoxicity (2 arms), sponsored by Damanhour University. Primary endpoints: Nuclear Factor Kappa B at 6 months and N-terminal pro b-type natriuretic peptide at 6 months. Started Mar 2023; status: completed.
02
Drugs
montelukast
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT05959889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959889.